Substance / Medication

Grazoprevir

SNOMED 716041004 UMLS C4080053

Overview

Active Ingredient

grazoprevir

RxNorm CUI

1734630

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Viral hepatitis C

Chronic type C viral hepatitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

102 trials linked to this intervention

102

Total Trials

Recruiting

With Results

Recent Trials

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

NCT00001854Phase 4Completed50 enrolled

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093Phase 4Completed50 enrolled

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636Phase 4Completed1469 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649Phase 4Completed188 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568Phase 4Completed57 enrolled

View all 102 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.

Liu Jinyu, Guo Min, Ke Lei et al. · Front Public Health · 2022

PMID: 35646774Meta-AnalysisFull text (PMC)

Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.

Nangia Gayatri, Vierling John M, Kwo Paul et al. · J Viral Hepat · 2020

PMID: 32594612Meta-Analysis

Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.

Evon Donna M, Dong Meichen, Reeve Bryce B et al. · J Viral Hepat · 2022

PMID: 35657133RCT

Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.

Pijnenburg Daniëlle W M, van Seyen Minou, Abbink Evertine J et al. · J Antimicrob Chemother · 2020

PMID: 32544221RCTFull text (PMC)

An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.

Huang Chung-Feng, Hung Chao-Hung, Cheng Pin-Nan et al. · J Infect Dis · 2019

PMID: 30957170RCT

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.

Foster Graham R, Agarwal Kosh, Cramp Matthew E et al. · Hepatology · 2018

PMID: 29473975RCT

Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network.

Flamm S L, Bacon B, Curry M P et al. · Aliment Pharmacol Ther · 2018

PMID: 29665097RCT

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

Yeh Wendy W, Fraser Iain P, Jumes Patricia et al. · Clin Ther · 2018

PMID: 29703432RCT

Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Gane E, Ben Ari Z, Mollison L et al. · J Viral Hepat · 2016

PMID: 27291249RCT

Validated LC/MS method for simultaneous determination of elbasvir and grazoprevir in human plasma.

Labidi Aymen, Bensghaier Rafika, Jebali Sami et al. · Ann Pharm Fr · 2024

PMID: 38823440Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Grazoprevir (substance)
SNOMED CT: 716041004
UMLS CUI: C4080053
RxNorm CUI: 1734630

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

102

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.